DE60141045D1 - Auf rtvp basierende zusammensetzungen und verfahren zur behandlung von prostata-krebs - Google Patents

Auf rtvp basierende zusammensetzungen und verfahren zur behandlung von prostata-krebs

Info

Publication number
DE60141045D1
DE60141045D1 DE60141045T DE60141045T DE60141045D1 DE 60141045 D1 DE60141045 D1 DE 60141045D1 DE 60141045 T DE60141045 T DE 60141045T DE 60141045 T DE60141045 T DE 60141045T DE 60141045 D1 DE60141045 D1 DE 60141045D1
Authority
DE
Germany
Prior art keywords
rtvp
mrtvp
prostate cancer
mouse
activities
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60141045T
Other languages
English (en)
Inventor
Timothy C Thompson
Chengzhen Ren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Application granted granted Critical
Publication of DE60141045D1 publication Critical patent/DE60141045D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747Apoptosis related proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60141045T 2000-06-08 2001-06-08 Auf rtvp basierende zusammensetzungen und verfahren zur behandlung von prostata-krebs Expired - Lifetime DE60141045D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20998900P 2000-06-08 2000-06-08
PCT/US2001/018487 WO2002006344A2 (en) 2000-06-08 2001-06-08 Rtvp based compositions and methods for the treatment of prostate cancer

Publications (1)

Publication Number Publication Date
DE60141045D1 true DE60141045D1 (de) 2010-02-25

Family

ID=22781163

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60141045T Expired - Lifetime DE60141045D1 (de) 2000-06-08 2001-06-08 Auf rtvp basierende zusammensetzungen und verfahren zur behandlung von prostata-krebs

Country Status (7)

Country Link
US (2) US20020052025A1 (de)
EP (1) EP1355944B1 (de)
AT (1) ATE454400T1 (de)
AU (1) AU2001266767A1 (de)
CA (1) CA2412183C (de)
DE (1) DE60141045D1 (de)
WO (1) WO2002006344A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020052025A1 (en) * 2000-06-08 2002-05-02 Thompson Timothy C. RTVP based compositions and methods for the treatment of prostate cancer
US20050187153A1 (en) * 2001-06-08 2005-08-25 Baylor College Of Medicine RTVP based compositions and methods for the treatment of prostate cancer, autoimmunity and infectious disease
WO2005002413A2 (en) * 2003-07-01 2005-01-13 Bar Ilan University Methods and reagents for diagnosing gliomas and treating gliomas
US7824685B2 (en) * 2004-01-26 2010-11-02 Baylor College Of Medicine RTVP based compositions and methods for the treatment of prostate cancer
WO2007099529A1 (en) * 2006-02-28 2007-09-07 Sandisk Il Ltd Bookmarked synchronization of files
US8367052B2 (en) 2007-03-26 2013-02-05 General Regeneratives Holdings Inc. Methods for promoting protection and regeneration of bone marrow using CXCL9 and anti-CXCL9 antibodies
US20130156777A1 (en) * 2011-09-12 2013-06-20 Raymond A. Koski Glipr1 inhibitors and therapeutic uses thereof
US10256831B2 (en) 2016-09-21 2019-04-09 Analog Devices Global Method and apparatus to reduce effect of dielectric absorption in SAR ADC
WO2020033536A1 (en) * 2018-08-07 2020-02-13 Glipper Oncology Research, Inc. Compositions of glipr fusion proteins and methods for the treatment of prostate cancer
USD947732S1 (en) 2020-08-04 2022-04-05 Polaris Industries Inc. Hood for an off-road vehicle

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789200A (en) * 1996-10-31 1998-08-04 Smithkline Beecham Corporation Human ETS family member, ELF3
US5856130A (en) * 1996-12-26 1999-01-05 Incyte Pharmaceuticals, Inc. Human pathogenesis-related protein
AU3316600A (en) 1999-02-22 2000-09-21 Torben F. Orntoft Gene expression in bladder tumors
US20020052308A1 (en) 1999-03-12 2002-05-02 Rosen Craig A. Nucleic acids, proteins and antibodies
US20030219743A1 (en) 2000-05-18 2003-11-27 Tang Y. Tom Novel nucleic acids and polypeptides
US20020052025A1 (en) 2000-06-08 2002-05-02 Thompson Timothy C. RTVP based compositions and methods for the treatment of prostate cancer
IT1318937B1 (it) * 2000-09-27 2003-09-19 Getters Spa Metodo per la produzione di dispositivi getter porosi con ridottaperdita di particelle e dispositivi cosi' prodotti
US20030119009A1 (en) 2001-02-23 2003-06-26 Stuart Susan G. Genes regulated by MYCN activation
US6783969B1 (en) 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
WO2003029468A1 (en) 2001-10-02 2003-04-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
JP2003135075A (ja) 2001-11-05 2003-05-13 Research Association For Biotechnology 新規な全長cDNA
US20040029151A1 (en) 2002-04-09 2004-02-12 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
US7601806B2 (en) 2003-06-09 2009-10-13 Baylor College Of Medicine RTVP-GliPR-like compositions and methods for the detection, treatment and prevention of prostate cancer
WO2005002413A2 (en) 2003-07-01 2005-01-13 Bar Ilan University Methods and reagents for diagnosing gliomas and treating gliomas

Also Published As

Publication number Publication date
EP1355944B1 (de) 2010-01-06
US7645452B2 (en) 2010-01-12
AU2001266767A1 (en) 2002-01-30
WO2002006344A2 (en) 2002-01-24
WO2002006344A3 (en) 2003-08-21
CA2412183A1 (en) 2002-01-24
ATE454400T1 (de) 2010-01-15
CA2412183C (en) 2010-08-03
US20040009508A1 (en) 2004-01-15
EP1355944A2 (de) 2003-10-29
US20020052025A1 (en) 2002-05-02

Similar Documents

Publication Publication Date Title
Jang et al. Breast cancer cell–derived soluble CD44 promotes tumor progression by triggering macrophage IL1β production
Chang et al. Concanavalin A induces autophagy in hepatoma cells and has a therapeutic effect in a murine in situ hepatoma model
Sharma et al. Immunohistochemical evaluation of mast cells and angiogenesis in oral squamous cell carcinoma
MX9804009A (es) Inhibicion de crecimiento tumoral por oligonucleotidos de antisentido para il-8 y receptor de il-8.
DE60141045D1 (de) Auf rtvp basierende zusammensetzungen und verfahren zur behandlung von prostata-krebs
Laakkonen et al. Peptide targeting of tumor lymph vessels
CY1107074T1 (el) Συνθεση εναντιομερων 4-αμινο-θαλιδομιδης
CA2311409A1 (en) Treatment with anti-erbb2 antibodies
MXPA02011379A (es) Ensayo de deteccion de genes para mejorar la probabilidad de una respuesta efectiva a terapia de cancer con el antagonista erbb.
WO2003027094A3 (en) Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
WO2004048525A3 (en) Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
DK1187918T3 (da) TEK-antagonister
RS105304A (en) Methods of treating angiogenesis,tumor growth,and metastasis
RU2015149285A (ru) Схемы дозирования иммуноконъюгата anti-folr1
DE69921130D1 (de) Verfahren und stoffe zur behandlung des prostatakarzinomes
Yin et al. RETRACTED: Resibufogenin suppresses growth and metastasis through inducing caspase‐1‐dependent pyroptosis via ROS‐mediated NF‐κB suppression in non‐small cell lung cancer
DE60328772D1 (de) Epothilonderivat zur behandlung von hepatoma und anderen krebserkrankungen
DE60136212D1 (de) Diagnose und behandlung von tumor-suppressor assoziierten krankheiten
Reichrath et al. Notch-signaling and nonmelanoma skin cancer: an ancient friend, revisited
SG148190A1 (en) Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer
ATE462441T1 (de) Saposin c und rezeptoren als ziele für die behandlung von gutartigen und bösartigen erkrankungen
Jindal et al. Heat shock proteins in pathology: a review
JP2018509469A5 (de)
ATE293985T1 (de) Verwendung von extrakten aus cimicifuga-arten als organselektives arzneimittel zur behandlung von sexualhormonabhängigen erkrankungen des urogenitaltraktes
Zheng et al. IGHG1 functions as an oncogene in tongue squamous cell carcinoma via JAK1/STAT5 signaling.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition